Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986497 · 1 trial · 2 indications
The combination therapy included BMS-986497 and Azacitidine
The triple combination therapy included BMS-986497, Azacitidine and Venetoclax.
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose Escalation BMS-986497 (Monotherapy) | EXPERIMENTAL | - |
| Part 2, Cohort A: Dose Expansion BMS-986497 (Combination Therapy) | EXPERIMENTAL | - |
| Part 2, Cohort B: Dose Expansion BMS-986497 (Triple Combination Therapy) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986497 | DRUG | Specified dose on specified days |
| Azacitidine | DRUG | Specified dose on specified days |
| Venetoclax | DRUG | Specified dose on specified days |
Inclusion Criteria: * Adults with primary or secondary relapsed and/or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). * Detectable levels of cluster of differentiation 33 (CD33) expression. * Failed alternative therapies with established benefit. * Eastern Cooperative On...
BMS-986497 is an investigational small molecule being developed for the treatment of Acute Myeloid Leukemia (AML). It is also being studied in Myelodysplastic Syndrome (MDS). The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BMS-986497 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with certain blood cancers.
BMS-986497 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is currently recruiting participants to evaluate the drug as a treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
BMS-986497 is being studied in a Phase 1 clinical trial with the identifier NCT06419634. This trial is evaluating the drug as a monotherapy and in combination with azacitidine and venetoclax in patients with relapsed or refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study is recruiting participants in the United States, Canada, France, and Spain.
Yes, BMS-986497 is also known as ORM-6151. The clinical trial NCT06419634 refers to the drug as BMS-986497 (ORM-6151), indicating that both names refer to the same investigational compound being developed by Bristol-Myers Squibb.